药物对比
Dapagliflozin vs Gliquidone
比较Dapagliflozin（Farxiga，SGLT2抑制剂）与Gliquidone（磺脲类）治疗2型糖尿病：机制、疗效、心血管/肾脏获益、低血糖风险及适用性。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when selecting an oral antidiabetic after metformin, especially weighing SGLT2 inhibitor cardiorenal benefits against sulfonylurea potency and cost.
结论
Dapagliflozin typically provides broader benefits for many patients, though Gliquidone can be a practical choice for straightforward glycemic control.
全部药物对比